JP2009526792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526792A5 JP2009526792A5 JP2008554652A JP2008554652A JP2009526792A5 JP 2009526792 A5 JP2009526792 A5 JP 2009526792A5 JP 2008554652 A JP2008554652 A JP 2008554652A JP 2008554652 A JP2008554652 A JP 2008554652A JP 2009526792 A5 JP2009526792 A5 JP 2009526792A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- alkoxy
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 92
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 38
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 32
- 229910052757 nitrogen Inorganic materials 0.000 claims 30
- 229910052760 oxygen Inorganic materials 0.000 claims 26
- 229910005965 SO 2 Inorganic materials 0.000 claims 22
- 125000005842 heteroatom Chemical group 0.000 claims 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 21
- 229910052717 sulfur Inorganic materials 0.000 claims 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 14
- 239000001301 oxygen Substances 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 13
- 125000004122 cyclic group Chemical group 0.000 claims 12
- 239000011593 sulfur Substances 0.000 claims 11
- 238000004519 manufacturing process Methods 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- -1 N (R31) Inorganic materials 0.000 claims 6
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 150000007854 aminals Chemical class 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000004129 fatty acid metabolism Effects 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 125000004980 cyclopropylene group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003142 primary aromatic amines Chemical class 0.000 claims 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006007046 | 2006-02-15 | ||
| PCT/EP2007/001211 WO2007093363A1 (en) | 2006-02-15 | 2007-02-13 | Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009526792A JP2009526792A (ja) | 2009-07-23 |
| JP2009526792A5 true JP2009526792A5 (enExample) | 2010-04-02 |
Family
ID=38024410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554652A Pending JP2009526792A (ja) | 2006-02-15 | 2007-02-13 | 新規なアザシクリル置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてのそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8828991B2 (enExample) |
| EP (1) | EP1986646A1 (enExample) |
| JP (1) | JP2009526792A (enExample) |
| KR (1) | KR20080095879A (enExample) |
| CN (1) | CN101370501A (enExample) |
| AR (1) | AR059521A1 (enExample) |
| AU (1) | AU2007214708A1 (enExample) |
| BR (1) | BRPI0707869A2 (enExample) |
| CA (1) | CA2636605A1 (enExample) |
| IL (1) | IL193341A0 (enExample) |
| TW (1) | TW200800920A (enExample) |
| UY (1) | UY30163A1 (enExample) |
| WO (1) | WO2007093363A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
| US8026240B2 (en) | 2007-09-11 | 2011-09-27 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole N-oxides |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| JP2012517459A (ja) | 2009-02-12 | 2012-08-02 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ | 代謝障害治療のためのカルジオトロフィン１の使用 |
| WO2010147234A1 (en) * | 2009-06-18 | 2010-12-23 | Banyu Pharmaceutical Co.,Ltd. | Diarylamide-spirodiamine derivative |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| HUP1100241A3 (en) | 2011-05-06 | 2013-12-30 | Richter Gedeon Nyrt | Oxetane substituted pyrimidones |
| US8933079B2 (en) * | 2012-03-07 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Pyridone and pyridazinone derivatives as anti-obesity agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| MXPA04004567A (es) * | 2001-11-13 | 2004-09-10 | Emisphere Tech Inc | Compuestos y composiciones de fenoxi amina para adminstrar agentes activos. |
| DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| EP1572212A2 (en) * | 2002-12-11 | 2005-09-14 | 7TM Pharma A/S | Quinoline compounds for use in mch receptor related disorders |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2543122A1 (en) * | 2003-10-23 | 2005-05-12 | Glaxo Group Limited | 3-(4-aminophenyl) thienopyrimid-4-one derivatives as mch r1 antagonists for the treatment of obesity, diabetes, depression and anxiety |
| US20050256124A1 (en) * | 2004-04-15 | 2005-11-17 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
-
2007
- 2007-02-13 WO PCT/EP2007/001211 patent/WO2007093363A1/en not_active Ceased
- 2007-02-13 KR KR1020087020096A patent/KR20080095879A/ko not_active Withdrawn
- 2007-02-13 AU AU2007214708A patent/AU2007214708A1/en not_active Abandoned
- 2007-02-13 CA CA002636605A patent/CA2636605A1/en not_active Abandoned
- 2007-02-13 TW TW096105358A patent/TW200800920A/zh unknown
- 2007-02-13 CN CNA2007800029667A patent/CN101370501A/zh active Pending
- 2007-02-13 JP JP2008554652A patent/JP2009526792A/ja active Pending
- 2007-02-13 EP EP07722801A patent/EP1986646A1/en not_active Withdrawn
- 2007-02-13 BR BRPI0707869-2A patent/BRPI0707869A2/pt not_active IP Right Cessation
- 2007-02-15 UY UY30163A patent/UY30163A1/es not_active Application Discontinuation
- 2007-02-15 AR ARP070100660A patent/AR059521A1/es not_active Application Discontinuation
-
2008
- 2008-08-10 IL IL193341A patent/IL193341A0/en unknown
- 2008-08-14 US US12/191,630 patent/US8828991B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526792A5 (enExample) | ||
| JP2009526793A5 (enExample) | ||
| JP2009526795A5 (enExample) | ||
| JP2009526794A5 (enExample) | ||
| RU2008136898A (ru) | Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств | |
| JP6431155B2 (ja) | フェノール誘導体及びその製造方法及び医薬的な応用 | |
| TWI712595B (zh) | 三環性螺化合物 | |
| AU2021200164B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| JP2021527638A (ja) | Ｂ型肝炎カプシドアセンブリモジュレーター | |
| JP2006517563A5 (enExample) | ||
| US9492440B2 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| JP2006501202A5 (enExample) | ||
| WO2009009501A3 (en) | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | |
| TW200811159A (en) | Therapeutic compounds | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| NO20091681L (no) | Modulatorer av glukortikoidreseptoren, AP-1, og/eller NF-kappaB aktivitet og anvendelse derav | |
| EP2271613A1 (de) | Hydroxymethylcyclohexylamine | |
| JP2012523395A5 (enExample) | ||
| RU2011145054A (ru) | Кристаллические формы саксаглиптина | |
| CA3226724A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
| JP2009040767A5 (enExample) | ||
| KR20210039417A (ko) | 치환된 테트라하이드로사이클로펜타[c]피롤, 치환된 디하이드로피롤리진, 이의 유사체, 및 이의 사용 방법 | |
| EP3233077A1 (en) | Dopamine d2 receptor ligands | |
| ES2665293T3 (es) | Compuesto para tratar estados con mediación alfa-adrenérgica | |
| CA3113573A1 (en) | Isoxazole carboxamide compounds and uses thereof |